Innovent Biologics Inc (6IB) — Cash Flow Reinvestment Rate
Innovent Biologics Inc (6IB) has a Cash Flow Reinvestment Rate of 9.11x as of December 2020, reinvesting €1.99 Billion (capex €211.14 Million plus investments €-1.78 Billion) from operating cash flow of €217.96 Million. Check 6IB cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Innovent Biologics Inc Cash Flow Reinvestment Rate (2023–2025)
Historical reinvestment intensity for Innovent Biologics Inc across 3 annual periods. Explore Innovent Biologics Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Innovent Biologics Inc (2023–2025)
Year-by-year capital reinvestment analysis for Innovent Biologics Inc. For live market cap and broader valuation context, see market cap of Innovent Biologics Inc.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.71x | €7.06 Billion | €10.00 Billion | €683.27 Million | ▼ -48.8% |
| 2024 | 1.38x | €1.78 Billion | €1.29 Billion | €1.71 Billion | ▼ -86.9% |
| 2023 | 10.51x | €1.55 Billion | €147.81 Million | €1.38 Billion | — |